Abortion Rights

Legislation Roe v. Wade State Legislation Supreme Court State Laws Reproductive Rights Public Opinion Ballot Measures Supreme Court Decisions Democratic Party Ohio Pro-Life Movement Judicial Decisions Republican Party Ballot Initiatives Reproductive Health Women's Health Supreme Court Rulings State Constitutional Amendments Anti-Abortion Movement Legal Challenges Constitutional Amendments Mifepristone Protests State Constitution State Constitutions Anti-Abortion Groups FDA Approval Legal Decisions State Elections Pro-life Movement Abortion Access Legal Battles Presidential Candidates Activism State Bans Abortion Bans Republican Stance Medication Abortion Women's Rights Legislative Actions Supreme Court Ruling State Politics Lawsuits Abortion Ballot Measures FDA Approval of Mifepristone Vice President Kamala Harris Michigan Reproductive Freedom Elections Legal Rulings State Restrictions Legislative Control Conservative Movements President Biden State Referendums State Supreme Court Advocacy Groups Legal Issues Supreme Court Decision 2024 Presidential Election Restrictions on Abortion Abortion Restrictions State Protections Federal Funding Opposition State Amendments Virginia U.S. Supreme Court Healthcare Policy State Legislatures Joe Biden National Abortion Ban State Constitution Amendments Conservative Opposition Advocacy Anti-Abortion Advocates 2024 Elections Republican Presidential Candidates Pro-Life Advocacy Donald Trump Federal Law Federal Ban Texas Abortion Ban Anti-Abortion Activism Kentucky Abortion Pill Roe v Wade Access to Medication Abortion Parental Rights State-Level Bans Dobbs Decision Texas Ohio Ballot Measure Republican Candidates Referendums Ohio Constitutional Amendment FDA Regulations Roe v. Wade Reversal State Budget

Virginia Judge Orders FDA to Reconsider 2023 Abortion‑Pill Restrictions

The court found the Risk Evaluation and Mitigation Strategy changes arbitrary and sent them back to the agency for further review, a ruling that could affect nationwide access to mifepristone.

Maison Des Champs Gets 45 Days for Scaling Las Vegas Sphere

Report Says Complications Rose After FDA Allowed Mail-Order Abortion Pills

Texas Law Takes Effect Allowing Private Suits Over Out-of-State Abortion Pills

Boulder Clinic Opens Offering Abortion Care Through 34 Weeks Under Colorado Law

FDA Launches Mifepristone Safety Review, Weighing How the Drug Is Dispensed

Report Finds 412 Post-Dobbs Prosecutions Tied to Pregnancy Across 16 States

FDA Opens Mifepristone Safety Review as Republicans Move to Curb Mail and Telehealth Access

Costco Declines to Stock Mifepristone Following Investor Campaign

Texas Man’s Wrongful-Death Suit Invokes Comstock Act to Challenge Telehealth Abortion Shield Laws